拥抱“十五五”新机遇：思拓凡四大举措，助力中国创新药走向全球

Core Insights - The forum focused on how to build a sustainable and resilient business ecosystem through open cooperation, technological innovation, and green transformation in the context of profound global economic changes [1] Group 1: Industry Trends - The Chinese biopharmaceutical industry has entered a period of innovation explosion, becoming a key source of global innovation [2][3] - In 2025, China approved 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historical high [2] - China ranks second globally in the number of new drugs under research, with clinical trials accounting for 30% of the global total [2] Group 2: Company Strategies - Cytiva aims to transition from being a product and service provider to a co-builder of capabilities through deep localization in China [3][4] - The company emphasizes the importance of innovation capability, focusing on end-to-end support for research and development [5][6] - Cytiva plans to achieve over 50% of its revenue in China from local manufacturing within the next 3-5 years, enhancing supply chain stability [6] Group 3: Ecosystem Development - Cytiva promotes industry ecosystem co-construction, launching the Global Biopharmaceutical Index to analyze challenges and opportunities in the sector [7] - The company has trained thousands of professionals in biopharmaceutical processes over the past 20 years, contributing to a robust talent pipeline [7] Group 4: Global Collaboration - The "15th Five-Year Plan" signals a commitment to high-level opening up, accelerating the pace of Chinese innovation reaching global markets [8][9] - Cytiva's "Sail Plan" aims to enhance compliance and global connectivity for Chinese enterprises, with plans to upgrade to "Sail Plan 2.0" [9]